Cantor Fitzgerald Remains a Buy on ProQR (PRQR)
Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on ProQR (PRQR – Research Report) yesterday. The company’s shares closed yesterday at $2.16.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Seedhouse covers the Healthcare sector, focusing on stocks such as Pharvaris, Apellis Pharmaceuticals, and Wave Life Sciences. According to TipRanks, Seedhouse has an average return of 8.4% and a 41.83% success rate on recommended stocks.
ProQR has an analyst consensus of Strong Buy, with a price target consensus of $9.33.
The company has a one-year high of $4.62 and a one-year low of $1.07. Currently, ProQR has an average volume of 474.4K.
Read More on PRQR:
Disclaimer & DisclosureReport an Issue
- ProQR Submits CTA for Phase 1 Study of AX-0810
- ProQR Shareholders Approve Key Resolutions at Annual Meeting
- ProQR Therapeutics Reports Q1 2025 Financial Results
- ProQR Therapeutics price target lowered to $9 from $15 at Oppenheimer
- ProQR’s Innovative RNA Editing Platform and Promising AX-0810 Program Drive Buy Rating
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.